Bidirectional Relationship Between Pancreatic Cancer and Diabetes Mellitus: a Comprehensive Literature Review

Overview

Journal Ann Med Surg (Lond)

Publisher Wolters Kluwer

Specialty Medical Education

Date 2024 Jun 7

PMID 38846873

Authors

Shady Sapoor

Mahmoud Nageh

Noran Magdy Shalma

Rana Sharaf

Nooran Haroun

Esraa Salama

Tungki Pratama Umar

Sadish Sharma

Reem Sayad

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer (PC) is a fatal malignant disease. It is well known that the relationship between PC and type 2 diabetes mellitus (T2DM) is a complicated bidirectional relationship. The most important factors causing increased risks of pancreatic cancer are hyperglycaemia, hyperinsulinemia, pancreatitis, and dyslipidemia. Genetics and the immune system also play an important role in the relationship between diabetes mellitus and pancreatic cancer. The primary contributors to this association involve insulin resistance and inflammatory processes within the tumour microenvironment. The combination of diabetes and obesity can contribute to PC by inducing hyperinsulinemia and influencing leptin and adiponectin levels. Given the heightened incidence of pancreatic cancer in diabetes patients compared to the general population, early screening for pancreatic cancer is recommended. Diabetes negatively impacts the survival of pancreatic cancer patients. Among patients receiving chemotherapy, it reduced their survival. The implementation of a healthy lifestyle, including weight management, serves as an initial preventive measure to mitigate the risk of disease development. The role of anti-diabetic drugs on survival is controversial; however, metformin may have a positive impact, especially in the early stages of cancer, while insulin therapy increases the risk of PC.

References

Hua X, Zhang H, Jia J, Chen S, Sun Y, Zhu X . Roles of S100 family members in drug resistance in tumors: Status and prospects. Biomed Pharmacother. 2020; 127:110156. DOI: 10.1016/j.biopha.2020.110156. View

Xu B, Wang S, Li R, Chen K, He L, Deng M . Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2. Cell Death Dis. 2017; 8(5):e2797. PMC: 5520701. DOI: 10.1038/cddis.2017.176. View

Olesen S, Poulsen J, Novovic S, Nojgaard C, Kalaitzakis E, Jensen N . Multiple risk factors for diabetes mellitus in patients with chronic pancreatitis: A multicentre study of 1117 cases. United European Gastroenterol J. 2020; 8(4):453-461. PMC: 7226693. DOI: 10.1177/2050640620901973. View

El Nakeeb A, Hamed H, Shehta A, Askr W, Dosoky M, Said R . Impact of obesity on surgical outcomes post-pancreaticoduodenectomy: a case-control study. Int J Surg. 2014; 12(5):488-93. DOI: 10.1016/j.ijsu.2014.01.017. View

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

Yu Q, Zhang Z, Zhang H . Effect of Glucose Variability on Pancreatic Cancer Through Regulation of COL6A1. Cancer Manag Res. 2021; 13:1291-1298. PMC: 7884946. DOI: 10.2147/CMAR.S293473. View

Shen B, Li Y, Sheng C, Liu L, Hou T, Xia N . Association between age at diabetes onset or diabetes duration and subsequent risk of pancreatic cancer: Results from a longitudinal cohort and mendelian randomization study. Lancet Reg Health West Pac. 2022; 30:100596. PMC: 9677075. DOI: 10.1016/j.lanwpc.2022.100596. View

Wang Z, Shen W, Li X, Feng Y, Qian K, Wang G . The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells. Drug Des Devel Ther. 2020; 14:3099-3110. PMC: 7410396. DOI: 10.2147/DDDT.S242557. View

Kern P, Di Gregorio G, Lu T, Rassouli N, Ranganathan G . Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes. 2003; 52(7):1779-85. DOI: 10.2337/diabetes.52.7.1779. View

10.

Korc M . Pathogenesis of Pancreatic Cancer-Related Diabetes Mellitus: Quo Vadis?. Pancreas. 2019; 48(5):594-597. PMC: 6620768. DOI: 10.1097/MPA.0000000000001300. View

11.

Crotty S . T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014; 41(4):529-42. PMC: 4223692. DOI: 10.1016/j.immuni.2014.10.004. View

12.

Rivlin N, Brosh R, Oren M, Rotter V . Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer. 2011; 2(4):466-74. PMC: 3135636. DOI: 10.1177/1947601911408889. View

13.

Ryu T, Park J, Scherer P . Hyperglycemia as a risk factor for cancer progression. Diabetes Metab J. 2014; 38(5):330-6. PMC: 4209346. DOI: 10.4093/dmj.2014.38.5.330. View

14.

Preziosi G, Oben J, Fusai G . Obesity and pancreatic cancer. Surg Oncol. 2014; 23(2):61-71. DOI: 10.1016/j.suronc.2014.02.003. View

15.

Li D . Diabetes and pancreatic cancer. Mol Carcinog. 2011; 51(1):64-74. PMC: 3238796. DOI: 10.1002/mc.20771. View

16.

Sharma A, Kandlakunta H, Nagpal S, Feng Z, Hoos W, Petersen G . Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. Gastroenterology. 2018; 155(3):730-739.e3. PMC: 6120785. DOI: 10.1053/j.gastro.2018.05.023. View

17.

Brouwers O, Niessen P, Ferreira I, Miyata T, Scheffer P, Teerlink T . Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats. J Biol Chem. 2010; 286(2):1374-80. PMC: 3020745. DOI: 10.1074/jbc.M110.144097. View

18.

Chen M, Tsan Y, Liou J, Lee Y, Wu M, Chiu H . Statins and the risk of pancreatic cancer in Type 2 diabetic patients--A population-based cohort study. Int J Cancer. 2015; 138(3):594-603. DOI: 10.1002/ijc.29813. View

19.

Hsieh M, Zhang L, Velasco-Gonzalez C, Yi Y, Pareti L, Trapido E . Impact of diabetes and modifiable risk factors on pancreatic cancer survival in a population-based study after adjusting for clinical factors. Cancer Causes Control. 2021; 33(1):37-48. DOI: 10.1007/s10552-021-01497-z. View

20.

Ozawa F, Friess H, Tempia-Caliera A, Kleeff J, Buchler M . Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen. 2001; 21(1):27-44. DOI: 10.1002/1520-6866(2001)21:1<27::aid-tcm4>3.0.co;2-9. View